KPTI
Karyopharm Therapeutics Inc.
Next earnings Aug 10, 2026 · consensus $-1.34 EPS, $33.8M rev
Last earnings +0.6% on 2026-05-14
$10.21
▲ +7.93%$10.21▲ +133.11%
over 1Y
L $3.77EODHDH $10.21
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.9%
1W+13.4%
1M+13.7%
3M+86.3%
YTD+42.0%
1Y+133.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Conservative balance sheet (liabilities/equity -1.37x); but unprofitable (net margin -134.2%).
Karyopharm Therapeutics Inc. shows $146M in FY2025 revenue (+0.6% YoY), a -134.2% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $210M | $157M | $146M | $145M | $146M |
| Gross profit | — | — | — | — | — |
| Operating income | -$98.3M | -$142M | -$130M | -$119M | -$90.7M |
| Net income | -$124M | -$165M | -$143M | -$76.4M | -$196M |
| Diluted EPS | -$1.65 | -$2.02 | -$18.79 | -$14.00 | -$17.93 |
| Net margin | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$296M
EV / EBITDA—
EV / Sales2.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-104.7%
FCF yield-40.2%
Quality & risk
ROIC (est.)—
Free cash flow-$75.4M
Total debt$169M
Net cash-$109M
Altman Z-Score-23.73 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-85.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-05-28
- 8-K Earnings results2026-05-14
- 10-Q Quarterly report2026-05-14
- S-3 Shelf registration (potential raise)2026-05-04
- S-3 Shelf registration (potential raise)2026-05-04
- DEF 14A Proxy statement2026-04-13
- 8-K Other event2026-03-27
- 8-K Material agreement2026-03-24
- 8-K Material agreement2026-03-03
Recent filings
all on EDGAR ↗SCHEDULE 13G/AFiling2026-06-05open ↗8-KPeriod ending 2026-05-212026-05-28open ↗S-8Filing2026-05-27open ↗S-8Filing2026-05-27open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗SCHEDULE 13GFiling2026-05-15open ↗4Period ending 2026-05-132026-05-15open ↗
Frequently asked
- Is Karyopharm Therapeutics Inc. (KPTI) a buy?
- KPTI currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.37x); but unprofitable (net margin -134.2%).
- What is Karyopharm Therapeutics Inc.'s quality score?
- KPTI scores 37.529411764705884/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001503802, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 1:03:54 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.